doxorubicin hydrochloride

In this study, SP94-LCP/DOX&Bcl-2 siRNA was successfully prepared. It exhibited remarkable targeting ability and antitumor activity, significantly enhancing the therapeutic effect of doxorubicin and siRNA on HCC. The construction of this drug delivery system provided a novel strategy for the clinical treatment of HCC.

LA-based IMS demonstrate significant potential as chemotherapeutic agents for the treatment of breast cancer.

CD79B expression was independently associated with a poor response to R-CHOP therapy in non-GCB DLBCL. The positive association between TERT and LC3 suggests the presence of additional metabolic adaptation mechanisms supporting tumor survival.

KRT5+ cells form cancer organoids over successive passages, are tumorigenic in serial dilution xenograft assays, and are resistant to the antineoplastic agents, doxorubicin and cisplatin. Together, these findings support a model in which HGSC contains two hierarchically related cell populations: KRT5+, OPN-responsive CPCs and KRT5-, non-tumorigenic cells that form a niche producing OPN. Inhibiting pathways that sustain this niche may enable reduced dosing of highly toxic chemotherapeutic agents while enhancing therapeutic efficacy in HGSC.

P=N/A, N=12, Completed, UMC Utrecht | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting

P2, N=160, Active, not recruiting, University of Arkansas | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P3, N=640, Recruiting, Ruijin Hospital | Trial completion date: Sep 2025 --> Jun 2028 | Trial primary completion date: Sep 2025 --> Jun 2028

However, these effects were not consistently supported by functional or histopathological findings. Further studies using more severe or longer-term cardiotoxicity models are warranted to clarify its cardioprotective potential.

Herein, we developed a pH-responsive nanocascade reactor (DOX@Cu-SKH) based on a copper infinite coordination polymer, which was functionalized with hyaluronic acid (HA) to deliver doxorubicin (DOX) for achieving efficient synergistic chemotherapy and chemodynamic therapy (CT/CDT)...At the same time, sulfasalazine effectively inhibited glutathione peroxidase 4 (GPX4) activity, further amplifying oxidative stress in tumor cells. In vivo studies utilizing H22 tumor-bearing mouse model demonstrated that the combination of CT/CDT significantly suppressed tumor growth with 88.7% tumor inhibition. This study introduces a novel strategy for the direct construction of a nanocascade reactor that achieves efficient CT/CDT combination therapy.

P3, N=420, Recruiting, AstraZeneca

Based on a biomimetic "core-shell" nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug-loaded apoptotic bodies (ApoBDs)...Furthermore, through targeted blockade of the CD24/Siglec-10 immune axis, the nanoplatform enhances macrophage-mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti-tumour immunotherapy, demonstrating significant translational potential.